Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer

来源 :2016年北京市肿瘤放疗年会 | 被引量 : 0次 | 上传用户:dingdang_2
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Purpose: Brain metastasis (BM) with a cystic component from breast cancer is rare and largely uncharacterized.The purpose of this study was to identify the characteristics of cystic BM in a large cohort of breast cancer patients.Results: A total of 35 eligible patients with cystic BM and 255 patients with solid BM were analyzed.Three factors were significantly associated with an increased probability of developing cystic lesions: age at diagnosis ≤ 40 years, age at BM ≤ 45 years, and poor histological grade (p < 0.05).Patients with cystic metastasis were also characterized by a larger metastasis volume, a shorter progression-free survival (PFS) following their first treatment for BM, and poor overall survival after BM (p <0.05).Multivariate analysis further demonstrated that local control of cystic BM was only potentially achieved for HER2-negative primary tumors (p =0.084).Methods: Breast cancer patients with parenchymal BM were reviewed from consecutive cases treated at our institution.Cystic BM was defined when the volume of a cystic lesion was greater than 50% of the aggregated volume of all lesions present.Clinicopathologic and radiographic variables were correlated with development of cystic lesions and with prognosis of cystic BM.Conclusions: This study shows that cystic BM from breast cancer, a special morphological type of BM, had worse prognosis than the more commonly observed solid BM.Younger age and low tumor grade were associated with the development of cystic lesions.Further comprehensive research and management of cystic BM are warranted to improve its poor prognosis.
其他文献
目的:早期乳腺癌保乳术后患者的预后与放疗获益,分析相关因素对预后的影响.方法:回顾分析医院1999年至2013年收治的1697例保乳术后早期乳腺癌患者,均未行新辅助化疗.中位年龄46岁(22-88).20例(1.1%)手术切缘阳性.术后病理分期pT1和pT2分别为1271例(74.9%)和426例(25.1%),pN0,pN1、pN2和pN3分别为1234例(72.7%)、334例(19.7%)、
目的:每日两次放疗(45Gy/30f,1.5Gy/f)或每日一次放疗(60-70Gy/30-35f,2.0Gy/f)联合EP方案化疗是NCCN指南局限期小细胞肺癌(LS-SCLC)的标准治疗方案.CONVERT研究比较了LS-SCLC每日两次放疗(45Gy/30f)与每日一次放疗(66Gy/33f)联合EP方案化疗的疗效,结果显示:每日两次放疗与每日一次放疗3年生存率无显著性差异(43%和39%)
目的:通过对射波刀呼吸追踪治疗肺部肿瘤的应用、体会,总结射波刀对肺部肿瘤治疗的优势,为进一步的应用、推广提供临床依据.方法:选择2013年12月至2015年10月收治的42例进行射波刀呼吸追踪治疗的肺部肿瘤患者,观察评估本组患者3个月和6个月的有效率和毒副反应发生情况.结果:42例患者均顺利完成治疗.3个月有效率为94%,6个月有效率为95%.发生急性放射性肺炎2例约占本组病例的5%、急性放射性食
目的:比较肺癌放疗过程中四维CT与传统方法勾画靶区的治疗计划差异性.方法:选取医院2013-01/2013-12间20例肺癌放疗患者为研究对象,对其进行四维CT与普通螺旋CT扫描,并且应用两种方法划定靶区与制定治疗计划,比较两种不同方法测定靶区的体积,分析其差异.结果:四维CT扫描勾画计划靶区体积为(277.4±33.6)cm3,普通螺旋CT扫描勾画计划靶区体积为(295.3±34.1)cm3.计
目的:探讨程序性死亡受体(PD)-1单克隆抗体治疗食管癌术后、化疗后转移性淋巴结的疗效.方法:回顾性分析1例使用PD-1单克隆抗体(pembrolizumab)治疗食管癌术后、化疗后淋巴结转移的临床资料.结果:患者食管癌术后、化疗后仍存在淋巴结转移,化疗后4个月内给予pembrolizumab治疗(100mg静脉滴,每2周一次),治疗后4周期后疗效评价为SD,8周期后疗效评价为PR.结论:食管癌术
目的:对SCLC患者外周血微环境中肿瘤相关细胞因子IL-2,IL-6,TGF-β1,HIF-1,PD-1,PD-L1,CTLA-4在治疗前,以及治疗的第1-7周期的动态表达进行检测,从细胞因子水平明确肿瘤患者全身免疫状况;为免疫治疗与化疗的结合寻找最佳切入点,并对治疗决策的制定提供依据.方法:收集43例ED/LD期SCLC患者外周血,利用ELISA方法检测该组患者外周血中IL-2,IL-6,TGF
Objective:To determine the high-risk population of breast cancer brain metastasis accompanied with severe peritumoral brain edema, and to probe into the effects of peritumoral brain edema degree on th
会议
Previous studies have investigated the prognostic significance of B7 homolog 3 (B7-H3) in non-small cell lung cancer (NSCLC), however, the results remain controversial.This study was aimed to determin
The outcome of recurrent brain metastasis is dismal.This study aims to assess the clinical outcomes and toxicity of reirradiation as a salvage treatment for progressive brain metastasis in patients wi
The clinical outcomes of the sequential versus concurrenttherapy of targeted therapy andradiotherapy are still unconfirmedin patients with brain metastases (BM).To evaluate the role ofthe combination